跳至主要内容
临床试验/NL-OMON56099
NL-OMON56099招募中不适用

Skeletal muscle structure and function in relation to post-exertional malaise in patients with PASC and ME/CFS - STOP PASC-ME/CFS

Amsterdam UMC0 个研究点目标入组 82 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
82

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • In order to be eligible to participate in this study, a subject with PASC must
  • meet all of the following criteria:
  • * Non-hospitalized individuals with prior confirmed diagnosis of severe acute
  • respiratory coronavirus 2 (SARS-CoV-2) infection by reverse
  • transcription-polymerase chain reaction testing or serology (wantai) testing
  • * Individuals with diagnosed PASC by a post-covid physician
  • * >3 months of symptoms
  • * Post exertional malaise, according to the DSQ-PEM questionnaire or 1:1
  • interview with post-covid physician
  • * No symptoms present before confirmed diagnosis of severe acute respiratory
  • coronavirus 2
  • * Aged between 18-65 years
  • In order to be eligible to participate in this study, a subject with ME/CFS
  • must meet all of the following criteria:
  • * Fulfill the Canadian Consensus Criteria (CCC)
  • * Post exertional malaise, according to the DSQ-PEM questionnaire or 1:1
  • interview with post-covid physician
  • * >3 months of symptoms
  • * ME/CFS diagnosis <10 years ago
  • * Aged between 18-65 years
  • * Confirmed diagnosis of severe acute respiratory coronavirus2 (SARS-CoV-2)
  • infection by reverse transcription-polymerase chain reaction testing or
  • serology (wantai) testing
  • For the healthy controls:
  • * Aged between 18-65 years
  • * Confirmed diagnosis of severe acute respiratory coronavirus2 (SARS-CoV-2)
  • infection by reverse transcription-polymerase chain reaction testing or
  • serology (wantai) testing without admission

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • * History of asthma, stroke, chronic obstructive pulmonary disease, congestive
  • heart failure, heart surgery, or congenital heart diseases
  • * Severe illness (e.g., cancer, CHD, uncontrolled diabetes)
  • * Current treatment with drugs known to interfere with metabolism e.g. systemic
  • corticosteroids, statins, SGLT2 inhibitors, GLP1 receptor agonists or immune
  • modulatory drugs in the last three months.
  • * Severe psychiatric or mood disorders
  • * Are current smokers or have been a regular smoker within the last 12 months
  • * Insulin pump therapy
  • * Symptomatic autonomic or distal neuropathy
  • * BMI >35 due to adiposity, since this is known to cause difficulties in
  • obtaining muscle biopsies.
  • * Pregnancy
  • * Recent acute myocardial infarction (<6 months)
  • * Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or
  • second/third degree AV block) causing hemodynamic compromise
  • * Implantable pacemaker or other cardiac device with complete ventricular
  • * Uncontrolled heart failure with hemodynamic compromise
  • * Uncontrolled hypertension (Systolic Blood Pressure >150 mmHg and Diastolic
  • Blood Pressure > 100 mmHg on repeated measurements)
  • * Active infection, anaemia, severe renal dysfunction (estimated Glomerular
  • filtration rate <30 ml/min/1,73m2) likely to significantly impact on exercise
  • performance
  • * > 6 alcohol units per day or >14 alcohol units per week
  • * Use of anticoagulants or anti platelet therapy

研究者

发起方
Amsterdam UMC

相似试验